Belite Bio, Inc Belite Bio, Inc

Belite Bio, Inc

BLTE

Clasificación en acciones #2972
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Precio por acción
$154.84
Capitalización bursátil
$6.24B
Cambio (1 día)
5.09%
Cambio (1 año)
71.34%
País
US
Comercio Belite Bio, Inc (BLTE)

Categoría

Healthcare
Historial de desdoblamientos de acciones de Belite Bio, Inc (BLTE)
La acción Belite Bio, Inc (símbolo: BLTE) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Oct 20, 2026.
Una acción BLTE comprada antes de Oct 20, 2026 equivaldría hoy a 0 acciones BLTE.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL